Hyperbaric Oxygen Therapy for Multiple Sclerosis: Benefits and Evidence
Multiple sclerosis (MS) is a chronic demyelinating disease of the CNS. Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen at >1 atmosphere absolute (ATA) in a pressurized chamber.
Proposed Mechanisms in MS
- Improved tissue oxygenation: Reduces hypoxia in demyelinated lesions.
- Anti-inflammatory: Downregulates pro-inflammatory cytokines; modulates microglial activation.
- Neuroprotection/regeneration: May enhance remyelination and axonal survival via oxygen-dependent pathways.
- Quality of life: Some trials report reduced fatigue, improved mobility, bladder function.
Evidence Status
Clinical trials have yielded mixed results. Systematic reviews (Cochrane) conclude insufficient evidence to recommend HBOT as routine MS therapy. It is not FDA-approved for MS and is considered experimental.
Considerations
- Risks: barotrauma, oxygen toxicity, claustrophobia, cost, access.
- Should only be pursued in clinical trial settings or after thorough discussion with an MS specialist.
Multiple Sclerosis - Related Articles
- ADHD & Multiple Sclerosis: No Evidence of Increased Susceptibility
- Multiple Sclerosis (MS) Symptoms: Understanding the Signs
- Morphine for Multiple Sclerosis Pain Management: An Updated Perspective
- Multiple Sclerosis Treatments: Medications & Management
- Multiple Sclerosis (MS) Symptoms: Understanding the Signs
- ALS (Lou Gehrig's Disease): Symptoms, Diagnosis & Facts
- The Impact of a Lack of Diversity in MS Research